search
Back to results

Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19 (GO2 PEEP)

Primary Purpose

COVID-19

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
GO2 PEEP MOUTHPIECE
Sponsored by
Emory University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for COVID-19 focused on measuring Bidirectional oxygenation, Pulmonary compromise, Supplemental oxygen

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • COVID-19 positive
  • Oxygen saturation <92%
  • Able to provide informed consent
  • Receiving oxygen by non-rebreather mask
  • Not currently requiring intubation

Exclusion Criteria:

  • Unable or unwilling to provide informed consent
  • Cognitive impairment
  • Rapidly decompensating status requiring urgent or emergent higher level of care

Sites / Locations

  • Emory University Hospital
  • Emory St. Joseph's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment with GO2 PEEP MOUTHPIECE

Arm Description

Participants receiving treatment with the GO2 PEEP MOUTHPIECE

Outcomes

Primary Outcome Measures

Oxygen Saturation by Pulse Oximetry
Pulse oximetry is a way to assess whether or not a patient needs help breathing. Oxygen saturation levels for healthy individuals are 95% and above.

Secondary Outcome Measures

Respiratory Rate
The number of breaths per minute was assessed before treatment, during treatment, and 15 minutes after the end of treatment.
Heart Rate
Heart rate, in beats per minute, was assessed before treatment, during treatment, and 15 minutes after the end of treatment.
Blood Pressure
Systolic and diastolic blood pressure was assessed before treatment, during treatment, and 15 minutes after the end of treatment.
Count of Participants With Subjective Work of Breathing
Participants were observed for stridor, grunting, nasal flaring, or accessory muscle use. The presence of any of these indicates that increased effort is required for breathing.

Full Information

First Posted
March 31, 2020
Last Updated
February 16, 2021
Sponsor
Emory University
search

1. Study Identification

Unique Protocol Identification Number
NCT04331366
Brief Title
Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19
Acronym
GO2 PEEP
Official Title
GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
April 8, 2020 (Actual)
Primary Completion Date
August 31, 2020 (Actual)
Study Completion Date
August 31, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Emory University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to determine the safety, feasibility and efficacy of a bidirectional oxygenation Positive End Expiratory Pressure (PEEP) mouthpiece in coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen by non-rebreather mask.
Detailed Description
Severe cases of COVID-19 often mimic the typical course of Adult Respiratory Distress Syndrome (ARDS) and its predictable sequelae. These patients often require intubation and ventilator support in order to sustain adequate oxygenation. Once a COVID-19 patient is intubated, Positive End Expiratory Pressure (PEEP) is a mainstay of treatment and is used in order to improve lung function, treat underlying atelectasis, improve oxygenation, and improve survival. In fact, early clinical data as well as reports from front line physicians treating COVID-19 suggest that PEEP has been the most effective treatment modality. In many cases, PEEP has resulted in improved oxygenation and improved survival. PEEP decreases the propensity for the alveoli to collapse by increasing the air pressure in the lungs. This residual pressure in the lungs at the end of exhalation decreases shunting and allows for more complete gas exchange and improved oxygenation. In patients, PEEP is one of the safest ways to increase partial pressure of oxygen (PaO2) and is used on almost all modern ventilator settings. The GO2 PEEP MOUTHPIECE is a simple, comfortable, and straightforward mouthpiece with a bidirectional valve that effectively delivers PEEP with every breath. Early application of the GO2 PEEP MOUTHPIECE in non-intubated COVID-19 patients may improve outcomes and save lives. Furthermore, this device may allow for less strain on limited resources, especially ventilators. This PEEP mouthpiece could be employed under an oxygen non-rebreather mask to improve oxygenation and avoid intubation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19
Keywords
Bidirectional oxygenation, Pulmonary compromise, Supplemental oxygen

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
2 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment with GO2 PEEP MOUTHPIECE
Arm Type
Experimental
Arm Description
Participants receiving treatment with the GO2 PEEP MOUTHPIECE
Intervention Type
Device
Intervention Name(s)
GO2 PEEP MOUTHPIECE
Intervention Description
The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.
Primary Outcome Measure Information:
Title
Oxygen Saturation by Pulse Oximetry
Description
Pulse oximetry is a way to assess whether or not a patient needs help breathing. Oxygen saturation levels for healthy individuals are 95% and above.
Time Frame
Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)
Secondary Outcome Measure Information:
Title
Respiratory Rate
Description
The number of breaths per minute was assessed before treatment, during treatment, and 15 minutes after the end of treatment.
Time Frame
Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)
Title
Heart Rate
Description
Heart rate, in beats per minute, was assessed before treatment, during treatment, and 15 minutes after the end of treatment.
Time Frame
Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)
Title
Blood Pressure
Description
Systolic and diastolic blood pressure was assessed before treatment, during treatment, and 15 minutes after the end of treatment.
Time Frame
Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)
Title
Count of Participants With Subjective Work of Breathing
Description
Participants were observed for stridor, grunting, nasal flaring, or accessory muscle use. The presence of any of these indicates that increased effort is required for breathing.
Time Frame
Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: COVID-19 positive Oxygen saturation <92% Able to provide informed consent Receiving oxygen by non-rebreather mask Not currently requiring intubation Exclusion Criteria: Unable or unwilling to provide informed consent Cognitive impairment Rapidly decompensating status requiring urgent or emergent higher level of care
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey Miller, MD
Organizational Affiliation
Emory University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Emory University Hospital
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Emory St. Joseph's Hospital
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19

We'll reach out to this number within 24 hrs